Rapport Therapeutics, Inc
Price
FilingsNewest: 10-Q, Quarterly reportAug 5 →InsidersNo open-market buys. 10 insiders sold $39.6M, 45 of 48 sales on a 10b5-1 plan.→HoldersFMR 15.0%TRV GP V 13.1%ARCH Venture 7.8%→Financing →PeersClosest companies: SEPN, MBX, NEUP→
From the filings
Figures
- Net income
- −$137.2Mlast 12 months
- Operating cash flow
- −$80.3Mlast 12 months
- Cash and equivalents
- $63.6Mat the last balance sheet
- Shares outstanding
- 48.0M shareson issue